Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017326
|
| MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 3 | 6 |
| 2017 | 5 | 42 | 47 |
| 2018 | 7 | 36 | 43 |
| 2019 | 1 | 16 | 17 |
| 2020 | 3 | 27 | 30 |
| 2021 | 3 | 20 | 23 |
| 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. Clin Infect Dis. 2022 02 11; 74(3):472-478.
-
Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis. 2022 02 11; 74(3):544-552.
-
COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Am J Health Syst Pharm. 2022 01 05; 79(2):63-71.
-
The COVID-19 response in the United Arab Emirates: challenges and opportunities. Nat Immunol. 2021 09; 22(9):1066-1067.
-
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021 Aug 19; 22(1):550.
-
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther. 2021 09 01; 29(9):2794-2805.
-
The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Rev Anti Infect Ther. 2022 02; 20(2):211-229.
-
COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021 08; 20(8):1013-1025.
-
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. J Cardiovasc Pharmacol. 2021 07 01; 78(1):e12-e19.
-
Readability of Participant Informed Consent Forms and Informational Documents: From Phase 3 COVID-19 Vaccine Clinical Trials in the United States. Mayo Clin Proc. 2021 08; 96(8):2095-2101.